{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:34:52Z","timestamp":1793277292008,"version":"4.5.0"},"reference-count":67,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 overexpression. Historically, treatment options for TNBC have been limited, because of the absence of actionable targets. The addition of immune checkpoint inhibitors to chemotherapy improved outcomes for a subset of patients with metastatic PD-L1\u2013positive disease; however, a critical need for more effective therapies remains. Antibody-drug conjugates (ADCs) have been a promising advance in the management of advanced TNBC and are reshaping the landscape as they move earlier into the treatment algorithm. A greater understanding of the molecular heterogeneity of TNBC has enabled the pursuit of more targeted and personalized therapeutic strategies. Despite this, TNBC continues to have the least favorable outcomes compared with other breast cancer subtypes. This review highlights current evidence and future challenges in advanced TNBC, including optimizing therapeutic sequencing and the ongoing need for predictive biomarkers and novel agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-520506","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:59:10Z","timestamp":1775851150000},"source":"Crossref","is-referenced-by-count":4,"title":["Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape"],"prefix":"10.1200","volume":"46","author":[{"given":"Maeve A.","family":"Hennessy","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Terman","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dam\u00e9","family":"Idossa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"LeVee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Leon-Ferre","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"McArthur","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60892-6"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf034"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0228"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508959"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy517"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01035-z"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31774-X"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235936"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03630-w"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1019"},{"key":"e_1_3_2_29_2","unstructured":"Dent R Shao Z Schmid P et al.: First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Primary results from the randomised phase 3 TROPION-Breast02 trial in Presented at: 2025 ESMO Congress; October 17-21 2025; Berlin Germany. Abstract LBA21"},{"key":"e_1_3_2_30_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Breast Cancer, Version 1.2026","author":"NCCN","unstructured":"NCCN: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Breast Cancer, Version 1.2026. https:\/\/www.nccn.org"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142307"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251327992"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.978"},{"key":"e_1_3_2_34_2","article-title":"Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +\/- pembrolizumab in PD-L1\u2013 metastatic triple-negative breast cancer (mTNBC)","volume":"39","author":"Garrido-Castro AC","year":"2021","unstructured":"Garrido-Castro AC, Keenan TE, Li T, et al: Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +\/- pembrolizumab in PD-L1\u2013 metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 39, 2021 (suppl 15; abstr TPS1106)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO2-19-06"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251396656"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00748-5"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf220"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2771"},{"key":"e_1_3_2_42_2","article-title":"Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer","author":"Rampa DR","unstructured":"Rampa DR, Seo M, Ogata N, et al: Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer. Clin Cancer Res 10.1158\/1078-0432.CCR-25-3321 [epub ahead of print on January 27, 2026]","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1137"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P3-10-26"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.17.4704"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26576"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.031"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2098"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02075"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1609"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10933"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-241"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06143-5"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00368"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0465"},{"key":"e_1_3_2_58_2","article-title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial","author":"Schmid PS","unstructured":"Schmid PS, McArthur HL, Cort\u00e9s J, et al: Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial. Ann Oncol 10.1016\/j.annonc.2025.12.012 [epub ahead of print on December 19, 2025]","journal-title":"Ann Oncol"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw067"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3327"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3495"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7531"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1138"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104870"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P4-10-21"},{"key":"e_1_3_2_67_2","article-title":"Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC): Updated findings from the open-label, phase II study","author":"Ouyang Q","year":"2025","unstructured":"Ouyang Q, Wang X, Tian C, et al: Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC): Updated findings from the open-label, phase II study. ESMO-IO, 2025. Poster - 129P","journal-title":"ESMO-IO"},{"key":"e_1_3_2_68_2","doi-asserted-by":"crossref","unstructured":"Wu J Zhang J Tong Z et al: Interim overall survival of patients with locally advanced or metastatic triple-negative breast cancer treated with first-line PM8002\/BNT327 in combination with nab-paclitaxel in phase 1b\/2 study Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13 2024; San Antonio TX. Abstract PS3-08","DOI":"10.1158\/1557-3265.SABCS24-PS3-08"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-520506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:59:12Z","timestamp":1775851152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-520506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-520506"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-520506","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e520506"}}